Antares Pharma (ATRS) 3.11 $ATRS
Antares Pharma to Present at the UBS Global HealthCare Conference
Business Wire - Tue May 13, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer, will present at the UBS Global HealthCare Conference on Tuesday May 20, 2014 at 1:00 pm Eastern Time.
Antares Pharma Reports First Quarter 2014 Operating and Financial Results
Business Wire - Fri May 09, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ: ATRS) today reported operating and financial results for the first quarter ended March 31, 2014.
Antares Pharma to Present at the Bank of America Merrill Lynch 2014 Healthcare Conference
Business Wire - Wed May 07, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer, will present at the Bank of America Merrill Lynch 2014 Healthcare Conference on Wednesday May 14, 2014 at 8:40 am PDT.
Antares Pharma Announces Update to QuickShot Testosterone Program
Business Wire - Tue May 06, 7:30AM CDT
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that a meeting was held with the U.S. Food and Drug Administration (FDA) to discuss a registration study for the VIBEX QuickShot auto injector in testosterone deficient adult males. The study will include approximately 150 adult males with testosterone blood levels less than 300 ng/dL, and will begin recruitment in the third quarter of 2014. The study is designed to show that once-weekly self-administration of testosterone with the VIBEX QuickShot auto injector can safely achieve normal blood levels of testosterone in hypogonadal men.
Transdermal Drug Delivery Market & Clinical Pipeline Insight Report 2014 - Detailed Analysis of the $25 Billion Industry
M2 - Fri May 02, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bdr2kp/transdermal_drug) has announced the addition of the "Transdermal Drug Delivery Market & Clinical Pipeline Insight" report to their offering. Transdermal drug delivery system, over the past decades, has emerged as a major tool for treating diseases of the skin. The major underlying factor driving this method is that the human skin is the most readily accessible surface for the delivery of drugs. A transdermal patch is defined as a medicated adhesive patch which is placed on the skin for delivering a specific dose of medication through the layers of the skin and into the bloodstream. This patch is considered to be a self contained, discrete dosage form, when applied to the intact skin, would deliver the drug, through the skin at a controlled rate to the systemic circulation. Transdermal drug delivery method is a non-invasive method which transports the drug from the surface of the skin to the circulatory system. The most effective medium for absorbing the drug is known to be the human skin. Patches are made on the skin through which this entire process is carried out. There are different types of patches which are used to introduce the active ingredients through the skin into the circulatory system. The transdermal delivery system broadly includes all topically administered drug formulations. Transdermal drug delivery system has been proved to be efficient owing to its large advantages over other controlled drug delivery systems. Some of these advantages include the reduction of painful delivery and the first pass metabolism of the drugs. This system of drug delivery is considered to be user-friendly, convenient, and it offers the advantage of multi-day dosing. These factors have led to a significant increase in the rate of patient compliance. There has been a significant upward trend in the global market for transdermal drug delivery. The market for transdermal drug delivery was worth US$ 25 billion in 2013 and is further anticipated to surpass US$ 40 billion by 2018. The major factor driving such a significant growth in the market is the increasing number of transdermal drug delivery products introduced into the market and continuously delivering therapeutic benefits in the real sense to the patients across the globe. Inspite of the transdermal system being highly successful in niche market, in other therapeutic application areas, the growth of this segment has not been highly commendable. There is a huge potential which is attracting the various companies in the pharmaceutical and biotechnology space. There are many application areas which are currently being researched upon. Some of them are wound care, monitoring and diagnostic methods. In these areas, the skin is used as a major portal for the delivery of drugs into the human body. Thus, the application of this system of drug delivery is most likely to play a significant role in improving the quality of life. Key Topics Covered: 1. Introduction to Transdermal Drug Delivery 2. Transdermal Drug Delivery Mechanism 3. Why Need For Transdermal Drug Delivery? 4. Transdermal Drug Delivery Market Outlook 5. Transdermal Drug Delivery Market Dynamics 6. Future of Transdermal Drug Delivery Market 7. Guidelines/Regulations for Transdermal Drug Delivery 8. Transdermal Drug Delivery Clinical Trial Insight by Phase, Country & Target Indications 9. Marketed Transdermal Drug Profiles 10. Suspended & Discontinued Transdermal Drug Profiles 11. Competitive Landscape - Acrux, - ANI Pharmaceuticals - Antares Pharma - Bayer HealthCare Pharmaceuticals - Dermatrends Inc - Durect Corporation - Nuvo Research - Novartis - Phosphagenics - Zosano Pharma For more information visit http://www.researchandmarkets.com/research/bd...ermal_drug
Antares Pharma to Host First Quarter 2014 Operating and Financial Results Conference Call
Business Wire - Fri May 02, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its first quarter 2014 financial results before the market opens on Friday, May 9, 2014, and host a conference call shortly thereafter at 8:30 a.m. ET (Eastern Time) to discuss the results. Paul K. Wotton, Ph.D., President and Chief Executive Officer, and Robert F. Apple, EVP, Chief Financial Officer, and President of the Parenteral Products Division, will host the call.
Analysts View on Health Care Sector Equities -- Research on Becton Dickinson and Co., Thoratec, Haemonetics, and Antares Pharma
PR Newswire - Wed Apr 30, 11:46AM CDT
On Tuesday, April 29, 2014, the NASDAQ Composite ended at 4,103.54, up 0.72%, the Dow Jones Industrial Average finished the day 0.53% higher at 16,535.37, and the S&P 500 closed at 1,878.33, up 0.48%. The gains were board based as eight out of the ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 671.98, up 0.62%, and the index has advanced 4.72% in the previous three months. Investor-Edge has initiated coverage on the following equities: Becton Dickinson and Co. (NYSE: BDX), Thoratec Corp. (NASDAQ: THOR), Haemonetics Corp. (NYSE: HAE) and Antares Pharma Inc. (NASDAQ: ATRS). Free technical research on BDX, THOR, HAE and ATRS can be downloaded upon signing up at:
Antares Pharma to Present at the Deutsche Bank Securities, Inc. 39th Annual Health Care Conference
Business Wire - Thu Apr 24, 6:01AM CDT
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer, will present at the Deutsche Bank Securities, Inc. 39th Annual Health Care Conference on Wednesday, May 7, 2014 at 4:50 p.m. Eastern Time.
Drug-Exposure Limitations of Oral Methotrexate at Doses Greater Than or Equal to 15 Mg May Be Overcome with Subcutaneous Administration
Business Wire - Thu Apr 17, 6:01AM CDT
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that the Annals of the Rheumatic Diseases has published results from an open-label, head-to-head randomized, crossover study comparing the relative bioavailability, safety and tolerability of OTREXUP to oral methotrexate (MTX) in adult patients with rheumatoid arthritis (RA).
Antares Pharma Announces Additional Patent Coverage for OTREXUP
Business Wire - Wed Apr 16, 6:01AM CDT
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the issuance of U.S. Patents RE44846 and RE44847. These patents are reissued versions of U.S. Patents 7,744,582, and 7,776,015. Tracing back to inventions made in the late 1990's, the patents capture innovations in the field of auto injectors that originally established Antares Pharma's position as a leader and innovator in medical injection device technology. Importantly, these patents add protection to OTREXUP as well as Antares' pipeline products. Antares is taking steps to supplement the current Orange Book listings related to OTREXUP.
Global Insulin Delivery Devices Market to 2019
M2 - Wed Apr 09, 8:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h59w23/insulin_delivery) has announced the addition of the "Insulin Delivery Devices Market to 2019 - Simplified Pump Solutions and Low Cost Pens Represent Distinct Regional Growth Drivers" report to their offering. The global insulin delivery devices market was valued at $8.8 billion in 2012 and is forecast to reach $13.8 billion by 2019, at a CAGR of 7%. Simplified Pump Solutions and Low Cost Pens Represent Distinct Regional Growth Drivers Growth in developed economies such as the US and Europe is attributed to an increasing preference for insulin pumps and the uptake of technical advances such as artificial pancreas devices. Supply-side initiatives aim to develop artificial pancreas devices that closely mimic the pancreas by using rapid-acting insulin and multiple hormone-secreting devices for the effective control of blood glucose. The growth in developing economies is attributed to the high prevalence of diabetes and low penetration of insulin delivery devices in these countries. Collaborations among companies and research foundations such as the Juvenile Diabetes Research Foundation (JDRF) help foster innovation in the diabetes care devices market. Many of these collaborations aim to develop artificial pancreas devices that can effectively replace the pancreas, ensuring the effective management of diabetes. Emerging economies such as India and China are expected to grow at the fastest pace during the 2012-2019 forecast period. While developed economies will witness increasing uptake of technically advanced devices, emerging economies will continue to see increasing uptake for conventional insulin delivery devices such as insulin pens, due to their lower cost." Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Diabetes - Disease Overview 4 Diabetes - Epidemiology 5 Global Insulin Delivery Devices Market: Device Overview 6 Global Insulin Delivery Devices Market: Market Characterization 7 Global Insulin Delivery Devices Market: Segment Analysis and Forecasts 8 Global Insulin Delivery Devices Market: Country Analysis and Forecasts 9 Global Insulin Delivery Devices Market: Reimbursement System 10 Global Insulin Delivery Devices Market: Competitive Landscape Companies Mentioned - Abbott Laboratories - Animas - Antares Pharma - Asante Solutions - Becton, Dickinson and Company - Bioject Medical Technologies - Eli Lilly - F. Hoffmann-La Roche - Injex - Equidyne Systems - Insulet - Medtronic - Novo Nordisk (Subsidiary of Novo A/S) - Owen Mumford - Sanofi - Shanghai Fosun Pharmaceutical - Tandem Diabetes Care - Tonghua Dongbao Pharmaceutical - Ypsomed For more information visit http://www.researchandmarkets.com/research/h5...n_delivery
Antares Pharma secures second milestone payment from LEO Pharma following launch of OTREXUP for treating psoriasis
M2 - Thu Mar 13, 6:05AM CDT
Pharmaceutical company Antares Pharma (NasdaqCM:ATRS) said on Wednesday that it has received a second milestone payment of USD5m under its dermatology partnership with LEO Pharma.
Antares Pharma Reports Fourth Quarter and Full Year 2013 Operating and Financial Results
Business Wire - Thu Mar 13, 6:01AM CDT
Antares Pharma, Inc. (NASDAQ: ATRS) today reported operating and financial results for the fourth quarter and full year ended December 31, 2013.
Antares Pharma Receives Second Milestone Payment from LEO Pharma in OTREXUP Collaboration
Business Wire - Wed Mar 12, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the receipt of a second milestone payment of $5 million from LEO Pharma. The milestone payment was received in connection with the launch of OTREXUP and the achievement of a specific percentage of patient lives covered by managed care organizations. To date, Antares has received $10 million in milestone payments from LEO Pharma.
Medac Pharma, Inc. Announces the Issuance of U.S. Patent for Treating Autoimmune Diseases with Concentrated Methotrexate Solutions of More Than 30 mg/ml
PR Newswire - Tue Mar 11, 9:17AM CDT
Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announces the issuance, via its parent company, medac GmbH, of U.S. patent 8,664,231 (the '231 patent) by the United States Patent and Trademark Office. The patent, entitled "Concentrated Methotrexate Solutions," is directed to a method for the treatment of inflammatory autoimmune diseases by subcutaneously administering methotrexate (MTX) at a concentration of more than 30 mg/ml.
Concise Analysis of the International Testosterone Replacement Therapy (TRT) Industry
M2 - Tue Mar 11, 4:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qpswzp/testosterone) has announced the addition of the "Concise Analysis of the International Testosterone Replacement Therapy (TRT) Industry" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Testosterone Replacement Therapy (TRT) in US$ Million. The global and the US markets are further analyzed by the following Product Segments: - Topicals - Patches - Others Company profiles are primarily based on public domain information including company URLs. The report profiles 30 companies including many key and niche players such as: - AbbVie Inc. - Acrux Ltd. - Actavis, Inc. - Antares Pharma, Inc. - Auxilium Pharmaceuticals, Inc. - Bayer HealthCare Pharmaceuticals - Clarus Therapeutics Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Outlook 2. Industry Overview 3. Product Landscape 4. Testosterone Deficiency And Trt - An Overview 5. Product Launches/Approvals 6. Recent Industry Activity 7. Focus On Select Players 8. Global Market Perspective III. Market 1. The United States 2. Canada 3. Europe 4. Asia-Pacific 5. Latin America 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 30 (including Divisions/Subsidiaries - 36) - The United States (20) - Canada (4) - Japan (1) - Europe (7) - France (1) - Germany (1) - The United Kingdom (2) - Italy (1) - Rest of Europe (2) - Asia-Pacific (Excluding Japan) (4) For more information visit http://www.researchandmarkets.com/research/qp...estosteron
Antares Pharma Announces LEO Pharma's Launch of OTREXUP (Methotrexate) Injection to Dermatologists for Adults with Psoriasis
Business Wire - Mon Mar 10, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ: ATRS) today announced LEO Pharma's launch of OTREXUPto Dermatologists, the first U.S. Food and Drug Administration (FDA) approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.
Antares Pharma to Host Fourth Quarter 2013 Operating and Financial Results Conference Call
Business Wire - Thu Mar 06, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its fourth quarter 2013 financial results before the market opens on Thursday, March 13, 2014, and host a conference call shortly thereafter at 8:30 a.m. ET (Eastern Time) to discuss the results. Paul K. Wotton, Ph.D., President and Chief Executive Officer, and Robert F. Apple, EVP, Chief Financial Officer, and President of the Parenteral Products Division, will host the call.
Antares Pharma to Present at the Cowen and Company 34th Annual Healthcare Conference
Business Wire - Wed Feb 26, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer, will present at the Cowen and Company 34th Annual Healthcare Conference on Wednesday March 5, 2014 at 8:00 am Eastern Time.
Today's Biggest Biotech Stories: Antares Pharma Inc., BioCryst Pharmaceuticals Inc., and Raptor Phar
George Budwell, The Motley Fool - Motley Fool - Thu Feb 20, 9:02AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! It's time to check in...
Antares Pharma to Present at the UBS Global HealthCare Conference
Business Wire - Tue May 13, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer, will present at the UBS Global HealthCare Conference on Tuesday May 20, 2014 at 1:00 pm Eastern Time.
Antares Pharma Reports First Quarter 2014 Operating and Financial Results
Business Wire - Fri May 09, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ: ATRS) today reported operating and financial results for the first quarter ended March 31, 2014.
Antares Pharma to Present at the Bank of America Merrill Lynch 2014 Healthcare Conference
Business Wire - Wed May 07, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer, will present at the Bank of America Merrill Lynch 2014 Healthcare Conference on Wednesday May 14, 2014 at 8:40 am PDT.
Antares Pharma Announces Update to QuickShot Testosterone Program
Business Wire - Tue May 06, 7:30AM CDT
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that a meeting was held with the U.S. Food and Drug Administration (FDA) to discuss a registration study for the VIBEX QuickShot auto injector in testosterone deficient adult males. The study will include approximately 150 adult males with testosterone blood levels less than 300 ng/dL, and will begin recruitment in the third quarter of 2014. The study is designed to show that once-weekly self-administration of testosterone with the VIBEX QuickShot auto injector can safely achieve normal blood levels of testosterone in hypogonadal men.
Transdermal Drug Delivery Market & Clinical Pipeline Insight Report 2014 - Detailed Analysis of the $25 Billion Industry
M2 - Fri May 02, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bdr2kp/transdermal_drug) has announced the addition of the "Transdermal Drug Delivery Market & Clinical Pipeline Insight" report to their offering. Transdermal drug delivery system, over the past decades, has emerged as a major tool for treating diseases of the skin. The major underlying factor driving this method is that the human skin is the most readily accessible surface for the delivery of drugs. A transdermal patch is defined as a medicated adhesive patch which is placed on the skin for delivering a specific dose of medication through the layers of the skin and into the bloodstream. This patch is considered to be a self contained, discrete dosage form, when applied to the intact skin, would deliver the drug, through the skin at a controlled rate to the systemic circulation. Transdermal drug delivery method is a non-invasive method which transports the drug from the surface of the skin to the circulatory system. The most effective medium for absorbing the drug is known to be the human skin. Patches are made on the skin through which this entire process is carried out. There are different types of patches which are used to introduce the active ingredients through the skin into the circulatory system. The transdermal delivery system broadly includes all topically administered drug formulations. Transdermal drug delivery system has been proved to be efficient owing to its large advantages over other controlled drug delivery systems. Some of these advantages include the reduction of painful delivery and the first pass metabolism of the drugs. This system of drug delivery is considered to be user-friendly, convenient, and it offers the advantage of multi-day dosing. These factors have led to a significant increase in the rate of patient compliance. There has been a significant upward trend in the global market for transdermal drug delivery. The market for transdermal drug delivery was worth US$ 25 billion in 2013 and is further anticipated to surpass US$ 40 billion by 2018. The major factor driving such a significant growth in the market is the increasing number of transdermal drug delivery products introduced into the market and continuously delivering therapeutic benefits in the real sense to the patients across the globe. Inspite of the transdermal system being highly successful in niche market, in other therapeutic application areas, the growth of this segment has not been highly commendable. There is a huge potential which is attracting the various companies in the pharmaceutical and biotechnology space. There are many application areas which are currently being researched upon. Some of them are wound care, monitoring and diagnostic methods. In these areas, the skin is used as a major portal for the delivery of drugs into the human body. Thus, the application of this system of drug delivery is most likely to play a significant role in improving the quality of life. Key Topics Covered: 1. Introduction to Transdermal Drug Delivery 2. Transdermal Drug Delivery Mechanism 3. Why Need For Transdermal Drug Delivery? 4. Transdermal Drug Delivery Market Outlook 5. Transdermal Drug Delivery Market Dynamics 6. Future of Transdermal Drug Delivery Market 7. Guidelines/Regulations for Transdermal Drug Delivery 8. Transdermal Drug Delivery Clinical Trial Insight by Phase, Country & Target Indications 9. Marketed Transdermal Drug Profiles 10. Suspended & Discontinued Transdermal Drug Profiles 11. Competitive Landscape - Acrux, - ANI Pharmaceuticals - Antares Pharma - Bayer HealthCare Pharmaceuticals - Dermatrends Inc - Durect Corporation - Nuvo Research - Novartis - Phosphagenics - Zosano Pharma For more information visit http://www.researchandmarkets.com/research/bd...ermal_drug
Antares Pharma to Host First Quarter 2014 Operating and Financial Results Conference Call
Business Wire - Fri May 02, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its first quarter 2014 financial results before the market opens on Friday, May 9, 2014, and host a conference call shortly thereafter at 8:30 a.m. ET (Eastern Time) to discuss the results. Paul K. Wotton, Ph.D., President and Chief Executive Officer, and Robert F. Apple, EVP, Chief Financial Officer, and President of the Parenteral Products Division, will host the call.
Analysts View on Health Care Sector Equities -- Research on Becton Dickinson and Co., Thoratec, Haemonetics, and Antares Pharma
PR Newswire - Wed Apr 30, 11:46AM CDT
On Tuesday, April 29, 2014, the NASDAQ Composite ended at 4,103.54, up 0.72%, the Dow Jones Industrial Average finished the day 0.53% higher at 16,535.37, and the S&P 500 closed at 1,878.33, up 0.48%. The gains were board based as eight out of the ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 671.98, up 0.62%, and the index has advanced 4.72% in the previous three months. Investor-Edge has initiated coverage on the following equities: Becton Dickinson and Co. (NYSE: BDX), Thoratec Corp. (NASDAQ: THOR), Haemonetics Corp. (NYSE: HAE) and Antares Pharma Inc. (NASDAQ: ATRS). Free technical research on BDX, THOR, HAE and ATRS can be downloaded upon signing up at:
Antares Pharma to Present at the Deutsche Bank Securities, Inc. 39th Annual Health Care Conference
Business Wire - Thu Apr 24, 6:01AM CDT
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer, will present at the Deutsche Bank Securities, Inc. 39th Annual Health Care Conference on Wednesday, May 7, 2014 at 4:50 p.m. Eastern Time.
Drug-Exposure Limitations of Oral Methotrexate at Doses Greater Than or Equal to 15 Mg May Be Overcome with Subcutaneous Administration
Business Wire - Thu Apr 17, 6:01AM CDT
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that the Annals of the Rheumatic Diseases has published results from an open-label, head-to-head randomized, crossover study comparing the relative bioavailability, safety and tolerability of OTREXUP to oral methotrexate (MTX) in adult patients with rheumatoid arthritis (RA).
Antares Pharma Announces Additional Patent Coverage for OTREXUP
Business Wire - Wed Apr 16, 6:01AM CDT
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the issuance of U.S. Patents RE44846 and RE44847. These patents are reissued versions of U.S. Patents 7,744,582, and 7,776,015. Tracing back to inventions made in the late 1990's, the patents capture innovations in the field of auto injectors that originally established Antares Pharma's position as a leader and innovator in medical injection device technology. Importantly, these patents add protection to OTREXUP as well as Antares' pipeline products. Antares is taking steps to supplement the current Orange Book listings related to OTREXUP.
Global Insulin Delivery Devices Market to 2019
M2 - Wed Apr 09, 8:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h59w23/insulin_delivery) has announced the addition of the "Insulin Delivery Devices Market to 2019 - Simplified Pump Solutions and Low Cost Pens Represent Distinct Regional Growth Drivers" report to their offering. The global insulin delivery devices market was valued at $8.8 billion in 2012 and is forecast to reach $13.8 billion by 2019, at a CAGR of 7%. Simplified Pump Solutions and Low Cost Pens Represent Distinct Regional Growth Drivers Growth in developed economies such as the US and Europe is attributed to an increasing preference for insulin pumps and the uptake of technical advances such as artificial pancreas devices. Supply-side initiatives aim to develop artificial pancreas devices that closely mimic the pancreas by using rapid-acting insulin and multiple hormone-secreting devices for the effective control of blood glucose. The growth in developing economies is attributed to the high prevalence of diabetes and low penetration of insulin delivery devices in these countries. Collaborations among companies and research foundations such as the Juvenile Diabetes Research Foundation (JDRF) help foster innovation in the diabetes care devices market. Many of these collaborations aim to develop artificial pancreas devices that can effectively replace the pancreas, ensuring the effective management of diabetes. Emerging economies such as India and China are expected to grow at the fastest pace during the 2012-2019 forecast period. While developed economies will witness increasing uptake of technically advanced devices, emerging economies will continue to see increasing uptake for conventional insulin delivery devices such as insulin pens, due to their lower cost." Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Diabetes - Disease Overview 4 Diabetes - Epidemiology 5 Global Insulin Delivery Devices Market: Device Overview 6 Global Insulin Delivery Devices Market: Market Characterization 7 Global Insulin Delivery Devices Market: Segment Analysis and Forecasts 8 Global Insulin Delivery Devices Market: Country Analysis and Forecasts 9 Global Insulin Delivery Devices Market: Reimbursement System 10 Global Insulin Delivery Devices Market: Competitive Landscape Companies Mentioned - Abbott Laboratories - Animas - Antares Pharma - Asante Solutions - Becton, Dickinson and Company - Bioject Medical Technologies - Eli Lilly - F. Hoffmann-La Roche - Injex - Equidyne Systems - Insulet - Medtronic - Novo Nordisk (Subsidiary of Novo A/S) - Owen Mumford - Sanofi - Shanghai Fosun Pharmaceutical - Tandem Diabetes Care - Tonghua Dongbao Pharmaceutical - Ypsomed For more information visit http://www.researchandmarkets.com/research/h5...n_delivery
Antares Pharma secures second milestone payment from LEO Pharma following launch of OTREXUP for treating psoriasis
M2 - Thu Mar 13, 6:05AM CDT
Pharmaceutical company Antares Pharma (NasdaqCM:ATRS) said on Wednesday that it has received a second milestone payment of USD5m under its dermatology partnership with LEO Pharma.
Antares Pharma Reports Fourth Quarter and Full Year 2013 Operating and Financial Results
Business Wire - Thu Mar 13, 6:01AM CDT
Antares Pharma, Inc. (NASDAQ: ATRS) today reported operating and financial results for the fourth quarter and full year ended December 31, 2013.
Antares Pharma Receives Second Milestone Payment from LEO Pharma in OTREXUP Collaboration
Business Wire - Wed Mar 12, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the receipt of a second milestone payment of $5 million from LEO Pharma. The milestone payment was received in connection with the launch of OTREXUP and the achievement of a specific percentage of patient lives covered by managed care organizations. To date, Antares has received $10 million in milestone payments from LEO Pharma.
Medac Pharma, Inc. Announces the Issuance of U.S. Patent for Treating Autoimmune Diseases with Concentrated Methotrexate Solutions of More Than 30 mg/ml
PR Newswire - Tue Mar 11, 9:17AM CDT
Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announces the issuance, via its parent company, medac GmbH, of U.S. patent 8,664,231 (the '231 patent) by the United States Patent and Trademark Office. The patent, entitled "Concentrated Methotrexate Solutions," is directed to a method for the treatment of inflammatory autoimmune diseases by subcutaneously administering methotrexate (MTX) at a concentration of more than 30 mg/ml.
Concise Analysis of the International Testosterone Replacement Therapy (TRT) Industry
M2 - Tue Mar 11, 4:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qpswzp/testosterone) has announced the addition of the "Concise Analysis of the International Testosterone Replacement Therapy (TRT) Industry" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Testosterone Replacement Therapy (TRT) in US$ Million. The global and the US markets are further analyzed by the following Product Segments: - Topicals - Patches - Others Company profiles are primarily based on public domain information including company URLs. The report profiles 30 companies including many key and niche players such as: - AbbVie Inc. - Acrux Ltd. - Actavis, Inc. - Antares Pharma, Inc. - Auxilium Pharmaceuticals, Inc. - Bayer HealthCare Pharmaceuticals - Clarus Therapeutics Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Outlook 2. Industry Overview 3. Product Landscape 4. Testosterone Deficiency And Trt - An Overview 5. Product Launches/Approvals 6. Recent Industry Activity 7. Focus On Select Players 8. Global Market Perspective III. Market 1. The United States 2. Canada 3. Europe 4. Asia-Pacific 5. Latin America 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 30 (including Divisions/Subsidiaries - 36) - The United States (20) - Canada (4) - Japan (1) - Europe (7) - France (1) - Germany (1) - The United Kingdom (2) - Italy (1) - Rest of Europe (2) - Asia-Pacific (Excluding Japan) (4) For more information visit http://www.researchandmarkets.com/research/qp...estosteron
Antares Pharma Announces LEO Pharma's Launch of OTREXUP (Methotrexate) Injection to Dermatologists for Adults with Psoriasis
Business Wire - Mon Mar 10, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ: ATRS) today announced LEO Pharma's launch of OTREXUPto Dermatologists, the first U.S. Food and Drug Administration (FDA) approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.
Antares Pharma to Host Fourth Quarter 2013 Operating and Financial Results Conference Call
Business Wire - Thu Mar 06, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its fourth quarter 2013 financial results before the market opens on Thursday, March 13, 2014, and host a conference call shortly thereafter at 8:30 a.m. ET (Eastern Time) to discuss the results. Paul K. Wotton, Ph.D., President and Chief Executive Officer, and Robert F. Apple, EVP, Chief Financial Officer, and President of the Parenteral Products Division, will host the call.
Antares Pharma to Present at the Cowen and Company 34th Annual Healthcare Conference
Business Wire - Wed Feb 26, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer, will present at the Cowen and Company 34th Annual Healthcare Conference on Wednesday March 5, 2014 at 8:00 am Eastern Time.
Today's Biggest Biotech Stories: Antares Pharma Inc., BioCryst Pharmaceuticals Inc., and Raptor Phar
George Budwell, The Motley Fool - Motley Fool - Thu Feb 20, 9:02AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! It's time to check in...
